• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ponatinib alone or with chemo-immunotherapy in heavily pre treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study.

作者信息

Kaiser Francesca, Lunghi Monia, Cardinali Deborah, Bellomarino Vittorio, Beldinanzi Marco, Starza Irene Della, Malfona Francesco, Basilico Claudia M, Defina Marzia, Mastaglio Sara, Giglio Fabio, Lazzarotto Davide, Salutari Prassede, Piccini Matteo, Cardinali Valeria, Pierini Antonio, Fracchiolla Nicola S, Di Biase Federica, Annunziata Mario, Di Trani Mariangela, Foa Robin, Chiaretti Sabina

机构信息

Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome.

Division of Hematology, Department of Translational Medicine, AOU Maggiore della Carità, Università del Piemonte Orientale, Novara.

出版信息

Haematologica. 2024 Dec 1;109(12):4095-4099. doi: 10.3324/haematol.2024.285258.

DOI:10.3324/haematol.2024.285258
PMID:39086308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609780/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b6/11609780/5e580616be4e/1094095.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b6/11609780/5e580616be4e/1094095.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b6/11609780/5e580616be4e/1094095.fig1.jpg

相似文献

1
Ponatinib alone or with chemo-immunotherapy in heavily pre treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study.波纳替尼单药或联合化疗免疫疗法治疗预处理严重的费城样急性淋巴细胞白血病：一项CAMPUS ALL真实世界研究
Haematologica. 2024 Dec 1;109(12):4095-4099. doi: 10.3324/haematol.2024.285258.
2
Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?在多靶点药物时代，强化化疗和异基因造血干细胞移植对于治愈费城染色体阳性的年轻急性淋巴细胞白血病是否必需？
Expert Rev Hematol. 2024 Jul;17(7):353-359. doi: 10.1080/17474086.2024.2357273. Epub 2024 May 20.
3
Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.波纳替尼治疗费城染色体阳性急性淋巴细胞白血病患者的疗效和安全性：来自单一机构的病例系列
Int J Hematol. 2021 Aug;114(2):199-204. doi: 10.1007/s12185-021-03156-0. Epub 2021 Apr 27.
4
Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study.基于 Ponatinib 的治疗方案在费城染色体阳性复发或难治性急性淋巴细胞白血病成人患者中的应用：真实世界 OPAL 研究的结果。
Leuk Lymphoma. 2020 Sep;61(9):2161-2167. doi: 10.1080/10428194.2020.1762876. Epub 2020 Jun 8.
5
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.Hyper-CVAD与波纳替尼联合作为费城染色体阳性急性淋巴细胞白血病患者的一线治疗：一项单中心2期研究的长期随访
Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.
6
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.Hyper-CVAD与波纳替尼联合作为费城染色体阳性急性淋巴细胞白血病患者的一线治疗：一项单中心2期研究。
Lancet Oncol. 2015 Nov;16(15):1547-1555. doi: 10.1016/S1470-2045(15)00207-7. Epub 2015 Sep 30.
7
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.波纳替尼在费城染色体阳性急性淋巴细胞白血病中的作用。
Expert Rev Anticancer Ther. 2015 Apr;15(4):365-73. doi: 10.1586/14737140.2015.1025256. Epub 2015 Mar 12.
8
Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.监测一名费城染色体阳性急性淋巴细胞白血病患儿的波纳替尼治疗情况。
Case Rep Oncol. 2021 Feb 15;14(1):24-28. doi: 10.1159/000511071. eCollection 2021 Jan-Apr.
9
Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study.比较 Ponatinib 和 Dasatinib 在伴有中枢神经系统复发的费城染色体阳性急性淋巴细胞白血病中的疗效和安全性：一项回顾性研究。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231165866. doi: 10.1177/15330338231165866.
10
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.Hyper-CVAD方案联合波纳替尼与Hyper-CVAD方案联合达沙替尼作为费城染色体阳性急性淋巴细胞白血病患者一线治疗的倾向评分分析
Cancer. 2016 Dec 1;122(23):3650-3656. doi: 10.1002/cncr.30231. Epub 2016 Aug 1.

本文引用的文献

1
Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.通过 IG/TR 基因重排进行可测量残留病分析：质量保证和更新的 EuroMRD 指南。
Leukemia. 2024 Jun;38(6):1315-1322. doi: 10.1038/s41375-024-02272-0. Epub 2024 May 14.
2
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.PEG aspargase 改良的成人急性淋巴细胞白血病风险导向方案：GIMEMA LAL1913 试验结果。
Blood Adv. 2023 Aug 22;7(16):4448-4461. doi: 10.1182/bloodadvances.2022009596.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
《世界卫生组织造血与淋巴组织肿瘤分类》第五版：淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
4
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.CRLF2 重排急性淋巴细胞白血病中 Janus 激酶的降解。
Blood. 2021 Dec 9;138(23):2313-2326. doi: 10.1182/blood.2020006846.
5
Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia.波纳替尼用于治疗Ph样急性淋巴细胞白血病。
Leuk Lymphoma. 2021 Mar;62(3):755-757. doi: 10.1080/10428194.2020.1842401. Epub 2020 Nov 5.
6
Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in -Rearranged Ph-like ALL.靶向 TSLP 诱导的酪氨酸激酶信号通路治疗费城染色体样 ALL。
Mol Cancer Res. 2020 Dec;18(12):1767-1776. doi: 10.1158/1541-7786.MCR-19-1098. Epub 2020 Aug 14.
7
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.酪氨酸激酶抑制剂在携带ABL类重排的Ph样急性淋巴细胞白血病中的疗效。
Blood. 2019 Oct 17;134(16):1351-1355. doi: 10.1182/blood.2019001244.
8
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.利用基于实时定量聚合酶链反应的预测统计模型快速鉴定 BCR/ABL1 样急性淋巴细胞白血病患者：临床、预后和治疗意义。
Br J Haematol. 2018 Jun;181(5):642-652. doi: 10.1111/bjh.15251. Epub 2018 Apr 19.
9
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.成人费城染色体样急性淋巴细胞白血病的高频率及不良预后
J Clin Oncol. 2017 Feb;35(4):394-401. doi: 10.1200/JCO.2016.69.0073. Epub 2016 Nov 21.
10
Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.药物反应谱分析可预测一名患有t(1;9)(q24;q34)相关B细胞急性淋巴细胞白血病的患者对波纳替尼的反应。
Blood Cancer J. 2015 Mar 13;5(3):e292. doi: 10.1038/bcj.2015.13.